News Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
10.5 ^DKK	+5.00%		+5.85%	-40.85%

Apr. 16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
Apr. 12	Curasight A/S Announces Board Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	Apr. 22	AQ
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	Apr. 16	AQ
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	Apr. 16	CI
Curasight announces change in the Board of Directors	Apr. 12	AQ
Curasight A/S Announces Board Changes	Apr. 12	CI
BioStock: Curasight cancels rights issue and evaluates alternative financing	Mar. 13	AQ
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	Mar. 11	AQ
Notice of Annual General Meeting 2024	Mar. 06	AQ
The subscription period in Curasight's rights issue begins today	Feb. 23	AQ
Curasight publishes information memorandum in connection with forthcoming rights issue	Feb. 22	AQ
Annual Report for the fiscal year 2023	Feb. 22	AQ
Year-end report October - December 2023	Feb. 22	AQ
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	Feb. 19	AQ
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	Feb. 13	PR
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	Feb. 13	AQ
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	Feb. 13	AQ
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	Feb. 13	CI
BioStock: Curasight gets first milestone payment from Curium	Feb. 02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Curasight A/S

Equities

CURAS

DK0061295797

Summary

Filters